WO2002034210A2 - Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing - Google Patents
Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing Download PDFInfo
- Publication number
- WO2002034210A2 WO2002034210A2 PCT/FR2001/003318 FR0103318W WO0234210A2 WO 2002034210 A2 WO2002034210 A2 WO 2002034210A2 FR 0103318 W FR0103318 W FR 0103318W WO 0234210 A2 WO0234210 A2 WO 0234210A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- carotenoid
- skin
- vitamin
- intended
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 106
- 235000021466 carotenoid Nutrition 0.000 title claims abstract description 70
- 150000001747 carotenoids Chemical class 0.000 title claims abstract description 70
- 230000032683 aging Effects 0.000 title claims abstract description 14
- 208000024891 symptom Diseases 0.000 title abstract 2
- 229960005070 ascorbic acid Drugs 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 159
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 47
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 47
- 239000011718 vitamin C Substances 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 31
- 102000008186 Collagen Human genes 0.000 claims abstract description 27
- 108010035532 Collagen Proteins 0.000 claims abstract description 27
- 229920001436 collagen Polymers 0.000 claims abstract description 27
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 230000015556 catabolic process Effects 0.000 claims abstract description 14
- 238000006731 degradation reaction Methods 0.000 claims abstract description 14
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 14
- 230000014509 gene expression Effects 0.000 claims abstract description 13
- 210000003491 skin Anatomy 0.000 claims description 70
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000002537 cosmetic Substances 0.000 claims description 21
- 235000013734 beta-carotene Nutrition 0.000 claims description 18
- 239000011648 beta-carotene Substances 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 18
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 18
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 17
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 17
- 235000012661 lycopene Nutrition 0.000 claims description 17
- 239000001751 lycopene Substances 0.000 claims description 17
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 17
- 229960004999 lycopene Drugs 0.000 claims description 17
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 17
- 210000004209 hair Anatomy 0.000 claims description 15
- 210000004207 dermis Anatomy 0.000 claims description 14
- 230000004936 stimulating effect Effects 0.000 claims description 13
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 claims description 12
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 102000005741 Metalloproteases Human genes 0.000 claims description 10
- 108010006035 Metalloproteases Proteins 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- WNCFBCKZRJDRKZ-UHFFFAOYSA-N 4-chloroindole-3-acetic acid Chemical compound C1=CC(Cl)=C2C(CC(=O)O)=CNC2=C1 WNCFBCKZRJDRKZ-UHFFFAOYSA-N 0.000 claims description 9
- 210000002510 keratinocyte Anatomy 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 230000009245 menopause Effects 0.000 claims description 7
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 claims description 6
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical compound C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 claims description 6
- 229930192334 Auxin Natural products 0.000 claims description 6
- 239000002363 auxin Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003279 phenylacetic acid Substances 0.000 claims description 6
- 229960003424 phenylacetic acid Drugs 0.000 claims description 6
- 239000003375 plant hormone Substances 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001553 phloroglucinol Drugs 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 3
- HXKWSTRRCHTUEC-UHFFFAOYSA-N 2,4-Dichlorophenoxyaceticacid Chemical compound OC(=O)C(Cl)OC1=CC=C(Cl)C=C1 HXKWSTRRCHTUEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003563 4-chloroindole-3-acetic acid Substances 0.000 claims description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 3
- 229930016911 cinnamic acid Natural products 0.000 claims description 3
- 235000013985 cinnamic acid Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- MBBOMCVGYCRMEA-UHFFFAOYSA-N tryptophol Chemical compound C1=CC=C2C(CCO)=CNC2=C1 MBBOMCVGYCRMEA-UHFFFAOYSA-N 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 2
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 claims description 2
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 2
- 230000011382 collagen catabolic process Effects 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 235000012680 lutein Nutrition 0.000 claims description 2
- 239000001656 lutein Substances 0.000 claims description 2
- 229960005375 lutein Drugs 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 2
- 235000010930 zeaxanthin Nutrition 0.000 claims description 2
- 239000001775 zeaxanthin Substances 0.000 claims description 2
- 229940043269 zeaxanthin Drugs 0.000 claims description 2
- LJAMDGCVZYDNHP-UHFFFAOYSA-N acetonitrile;1h-indole Chemical compound CC#N.C1=CC=C2NC=CC2=C1 LJAMDGCVZYDNHP-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 108060005980 Collagenase Proteins 0.000 abstract description 10
- 102000029816 Collagenase Human genes 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000835 fiber Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000013543 active substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- -1 filters Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229930013032 isoflavonoid Natural products 0.000 description 3
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 3
- 235000012891 isoflavonoids Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000003280 chronobiological effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- DMCPFOBLJMLSNX-UHFFFAOYSA-N indole-3-acetonitrile Chemical compound C1=CC=C2C(CC#N)=CNC2=C1 DMCPFOBLJMLSNX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- GDLBFKVLRPITMI-UHFFFAOYSA-N diazoxide Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000006224 matting agent Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960002304 thenalidine Drugs 0.000 description 1
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention relates to the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to treat the cutaneous signs of aging. , in particular the degradation of the skin and / or mucous membranes by inhibiting the activity and / or expression of collagenases and by increasing the synthesis of collagen.
- the invention also relates to a method of cosmetic treatment of the skin and / or mucous membranes.
- the skin In mammals in general, particularly in humans, the skin consists of two compartments, namely a compartment in relation to the outside, the epidemic, and n deep compartment which serves to support the epidermis, the dermis.
- the epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with solid support. It is also its nourishing element. It mainly consists of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, known as the fundamental substance, components synthesized by the fibroblast. There are also leukocytes, mast cells or tissue macrophages, it is also crossed by blood vessels and nerve fibers. In normal skin, that is to say non-pathological or scarring, the fibroblast is in a quiescent state. ie non-proliferative, not very active from a metabolic point of view and not mobile
- Collagen fibers largely ensure the solidity of the dermis. These fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures. The solidity of the dermis is largely due to the entanglement of collagen fibers packed against each other in all directions. Collagen fibers also participate in elasticity and especially in the tone of the skin and / or mucous membranes. The collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis. This thinning of the dermis is also due to pathological causes such as, for example, the hypersecretion of corticosteroid hormones, certain pathologies or vitamin deficiencies. It is also recognized that extrinsic factors such as ultraviolet rays, tobacco or certain treatments (Glucocorticoides, vitamin D and derivatives, for example) also have an effect on the skin and its collagen level.
- extrinsic factors such as ultraviolet rays, tobacco or certain treatments (Glucocorticoides, vitamin D and derivatives
- collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that has always been sought to combat, particularly in humans, preferring the appearance of smooth and taut skin.
- Collagenases are part of a family of enzymes called metalloproteinases (MMPs) which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and basal laminae at neutral pH (collagen, etastin, etc.). Very widely distributed in the living world, these enzymes are present, but weakly expressed, in normal physiological situations such as your organ growth and tissue renewal.
- the family of metalloproteinases consists of several well-defined groups based on their similarities in terms of structure and specificity of substrate (see Woessner JF, Faseb Journal, vol. 5 1991, 2145).
- collagenases intended for degrading fibrillar collagens MMP-1 or interstitial collagenase, MMP-8 or neutrophile collagenase, MMP-3 or collagenase 3
- gelatinases which degrade collagen type IV or any form of denatured collagen MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)
- stromelysins MMP-3 whose broad spectrum of activity is address to proteins of the extracellular matrix such as glycoproteins (fibronectin, laminin), proteoglycans, etc., 5 or even membrane metalloproteinases
- the main modifications concerning the dermis are a reduction in the level of collagen and the dermal thickness, that involves in the menopausal woman a thinning of the skin and / or mucous membranes. The woman then feels a sensation of "dry skin” or of skin 15 which pulls and there is an accentuation of the wrinkles and fine lines on the surface. The skin has a rough appearance on the palpatîon. Finally, the skin has reduced flexibility.
- cutaneous signs of aging means any modification of the external appearance of the skin due to aging, whether chronobiological and / or photo-induced, such as for example wrinkles and fine lines, withered skin, the skin
- One of the aims of the present invention is therefore to be able to have a product which makes it possible to treat, in mammals in general, particularly in man, preventively and / or curatively, the skin signs of aging, whether chronobiological or photo-induced, particularly thinning of the dermis and / or degradation of collagen fibers, by a stimulating effect on synthesis collagen and / or a collagenase inhibiting effect and if possible no significant side effects.
- the Applicant has now discovered that the combination of at least one carotenoid and vitamin C makes it possible to treat, in a preventive and / or curative manner, the skin signs of aging, whether chronological or photo-induced, particularly thinning of the dermis and / or degradation of collagen fibers, by a stimulating effect on collagen synthesis and / or A collagenase inhibiting effect.
- a remarkable property of the combination of the invention is that it has effects in greater proportions than those reasonably expected from the simple addition of the effects of each of these components taken separately.
- An advantage of this property is to allow a use in the composition of the invention of a quantity of each of the products less than what is generally accepted to use,
- the first object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to treat the signs skin of aging.
- a second object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to combat degradation of the collagen.
- a third object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to inhibit the expression of the proteases of the extracellular matrix, particularly metalloproteinases and even more particularly metalloproteinase type 1.
- a fourth object of the invention is the use of the combination in a composition or for the preparation of a composition of the combination of at least one carotenoid and vitamin C, the combination or the composition being intended to treat skin disorders linked to aging, in particular skin disorders of menopause,
- a fifth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to combat wrinkles and wrinkles.
- the sixth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to fight against withered skin .
- the seventh subject of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended for combating soft skin .
- the eighth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to fight against thinned skin. .
- the ninth subject of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended for combating dull skin and dull.
- a tenth subject of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to combat the lack of elasticity and / or tone of the skin,
- carotenoid is meant according to the invention both a carotenoid with provitamin A activity, and a carotenoid without provitamin A activity.
- the carotenoid can be a mixture of carotenoids with provitamin A activity and carotenoids without provitamin A activity. This mixture can be in any proportion.
- the carotenoid with provitamin A activity can be a mixture of carotenoids with provitamin A activity.
- This mixture can be in any proportion.
- the carotenoids with provitamin A activity there may be mentioned by way of example ⁇ -carotene or ⁇ -carotene,
- ⁇ -carotene is used.
- the carotenoid without provitamin A activity can be a mixture of carotenoids without provitamin A activity. This mixture can be in any proportion.
- the carotenoids without provitamin A activity mention may be made, for example, of zeaxanthin. cryptoxanthine, lutein or lycopene.
- lycopene is used.
- a carotenoid without provitamin A activity is used and even more preferably lycopene.
- Lycopene is a natural pigment found in ripe fruit, especially in tomatoes. It belongs to the carotenoid family and its structure is close to that of ⁇ -carotene.
- the role of lycopene in the ripening of fruits is known in the prior art Lycopene is used in compositions with bronzing activity for its role on the synthesis of melanin (WO 97/47278), in compositions intended for the treatment of the hair and / or acne for its activity on 5-reductases ( JP-2940964) or also as an anti-radical agent (JP-A- 8-283136.
- Lycopene can be in cis or trans chemical form.
- the carotenoid used according to the invention can be of natural or synthetic origin.
- natural origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element.
- an extract rich in lycopene is used, such as for example a tomato extract.
- synthetic origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained by chemical synthesis.
- the carotenoid When the carotenoid is of natural origin, it can be obtained from plant material from a whole plant grown in vivo or from in vitro culture.
- in vivo culture means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
- in vitro culture means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
- the selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
- a plant derived from culture in vivo is used.
- the carotenoid can be in alcoholic solution, in particular ethanolic.
- the carotenoid can also be in lipid (oil) or lipoalcoholic solution.
- a tomato extract rich in lycopene is used, prepared by the company Métaphar, marketed under the name LycOMato® consisting of an oleoresin extract (fatty phase) containing 6% of pure lycopene. .
- any preparation containing lycopene having the objective of improving the bioavailability of the latter.
- the amount of carotenoid that can be used according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
- the carotenoid in the pure state is in an amount representing from 10 "11 to 2 % to 20% of the total weight of the composition and preferably in an amount representing from 10 ' 10 % to 10% of the total weight of the composition.
- Vitamin C (or ascorbic acid) is known to stimulate the synthesis of collagen, by preventing, as a co-factor, the auto-inactivation of the enzymes lysine- and proline-hydroxylases and by increasing the synthesis of the rRNA of procolla fauxs L ascorbic acid (or vitamin C) is also known to stimulate the synthesis of elastin of the skin.
- Vitamin C or ascorbic acid
- ascorbic acid and / or its analogs can be used alone or in mixtures of any kind and any proportion and can be of natural or synthetic origin.
- Ascorbic acid is generally in L form, because it is more particularly in this form that it is found in the plant world.
- the amount of vitamin C usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
- vitamin C in the pure state perhaps in an amount representing from 10 " 10 10% to 20% of the total weight of the composition and preferably in an amount representing 10 " 8 % to 10% of the total weight of the composition.
- vitamin C is present in the form of a solution, for example a plant extract
- the skilled person will be able to adjust the amount of this solution in the composition according to the invention, so as to obtain the ranges of vitamin C concentrations described above.
- composition of the invention can be in any imaginable form, suitable both for topical application to the skin and / or mucous membranes and / or the hair and / or your hair as for administration by the oral route.
- composition of " the invention is intended for administration by the oral route.
- the composition of the invention can be a cosmetic or dermatological composition.
- the composition is a cosmetic composition.
- the composition is a cosmetic composition because it is intended to improve the general cutaneous appearance of the individual who uses it.
- the composition of the invention is a cosmetic composition intended for administration by the oral route,
- the composition of the invention can be in any suitable form, particularly in the form of an oral solution, a syrup, a tablet, a dragee, a capsule or a capsule or a nutritional food or a nutritional supplement.
- Said composition can also comprise at least one suitable excipient suitable for oral administration,
- the composition according to the invention obviously comprises a cosmetically acceptable carrier, that is to say a carrier compatible with the skin, the mucous membranes, the nails, the hair, the hairs and can be in all the galenic forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, of an oil-in-water or water-in emulsion oil or multiple, of an aqueous or oily gel, of a liquid, pasty or solid anhydrous product, of an oil dispersion in an aqueous phase using spherules, these spherules possibly being polymeric nanoparticles such than nanospheres and nanocapsules or better lipid vesicles of ionic and / or nonionic type.
- a cosmetically acceptable carrier that is to say a carrier compatible with the skin, the mucous membranes, the nails, the hair, the hairs and can be in all the galenic forms normally used for a topical application, in particular in the
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product, as a cleaning product, as a makeup product or even as a simple deodorant product,
- the composition of the invention may contain the adjuvants customary in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents.
- hydrophilic or lipophilic active agents preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, chelating agents, odor absorbers and coloring matters.
- the amounts of these various adjuvants are those conventionally used in the fields considered and for example from 0.01% to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.
- the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% of the total weight of the composition.
- Oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% of the total weight of the composition.
- emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitan tristearate.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers). acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes,
- composition can contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, plant extracts and hydroxy acids.
- hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, plant extracts and hydroxy acids.
- vitamin A As lipophilic active ingredients. retinol (vitamin A) and its derivatives, to opherol (vitamin E) and its derivatives, essential fatty acids, cerainides, essential oils, salicylic acid and its derivatives or even vitamins B 1 can be used, B6 and / or B12.
- composition of the invention at least one isoflavonoid, optionally a plant extract rich in isoflavonoids.
- a plant extract rich in isoflavonoids such as for example the soy extract (Glycisa max) available from Archer Daniels Midland Company under the name Novasoy ⁇ .
- a preferred composition of the invention comprises, among other ingredients, the combination of at least one carotenoid and vitamin C, a plant extract rich in isoflavonoids and -tocopherol.
- the composition of the invention comprises, among other ingredients, the combination of ⁇ -carotene and vitamin C, soy extract (Novasoy® from the company Archer Daniels Midland Company), and acetate d ' ⁇ -tocopherol.
- extracts of micro-organisms including in particular bacterial extracts such as those of non-photosynthetic filamentous bacteria,
- other compounds can also be added, namely for example your potassium channel openers such as diazoxide and mtnoxidil. spiroxazone, phospholipids such as lecithin, linoleic and linolenic acids, salicylic acid and its derivatives described in French patent FR 2 581 542, such as salicylic acid derivatives carrying an alkanoyl group having from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and their esters, lactones and their corresponding salts, anthralin, carotenoids, eicosatetraenoic and eicosatrienoic acids or their esters and amides, vitamin D and its derivatives.
- your potassium channel openers such as diazoxide and mtnoxidil.
- phospholipids such as lecithin, linoleic and linolenic acids
- composition of the invention can be, among others, added to the composition of the invention with other active agents intended in particular for pr évention and / or treatment of skin disorders.
- active agents include - agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradlol, kojic acid or hydroquinone; - Antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class;
- agents modulating bacterial adhesion to the skin and / or mucous membranes such as honey, in particular acacia honey and certain sugar derivatives; - antiparasitic agents, in particular metronidazole, crotamion or pyrethroids;
- antifungals in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconcon or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or even the octoprox;
- - steroidal anti-inflammatory agents such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid , acetaminophen or giycyrrhetinic acid;
- - anesthetic agents such as lidocaine hydrochloride and its derivatives
- - antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;
- - keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and generally fruit acids, and n-octanoyl-5-sa cyclic acid;
- - anti-free radical agents such as superoxide clismutases, certain metal chelators or ascorbic acid and its esters,
- anti-dandruff agents such as octopirox or zinc pyrithione
- - anti-acne drugs such as retinic acid or benzoyl peroxide.
- compositions such as substance P, CGRP or bradykmine antagonists or MO synthase inhibitors or sodium channel inhibitors, compounds described as being active in the treatment of sensitive skin and as having anti-irritant effects, in particular with regard to irritant compounds possibly present in the compositions.
- moisturizers such as polyols (for example glycerin), vitamins (for example D-panthenol), anti-inflammatory agents, soothing agents (allantoin, blueberry water), filters can be used UVA and UVB, matting agents (for example polydimethylorganosiloxanes partially crosslinked sold under the name KSG® by Shin Etsu) and their mixtures.
- polyols for example glycerin
- vitamins for example D-panthenol
- anti-inflammatory agents for example D-panthenol
- soothing agents allantoin, blueberry water
- filters can be used UVA and UVB, matting agents (for example polydimethylorganosiloxanes partially crosslinked sold under the name KSG® by Shin Etsu) and their mixtures.
- Anti-wrinkle active agents can also be added, and in particular tensing products such as vegetable proteins and their hydrolysates, in particular the soy protein extract sold under the name Eleseryl® by the company LSN or the oat derivative sold. under the name Reductine® by the company Silab.
- the skin is made up of many other components than collagen and fibroblasts, it turns out to be advantageous, when using the combination of the invention, to promote at the same time the synthesis of these other components such as for example lipids and / or promote the proliferation of other cellular components such as, for example, keratinocytes
- the subject of the invention is a cosmetic composition
- a cosmetic composition comprising, in a cosmetically acceptable medium, the combination of at least one carotenoid and vitamin C and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes.
- Said composition can be intended for use in the cosmetic or dermatological field, preferably in the cosmetic field.
- vitamin C and the carotenoid can be as described previously in the text
- Mention may be made, as product stimulating the synthesis of lipids, of plant hormones, such as auxins, or of compounds of plant origin, such as kinetic acid, and as product stimulating the proliferation of keratinocytes of compounds of plant origin, such as phloroglucinol.
- plant hormones such as auxins
- compounds of plant origin such as kinetic acid
- product stimulating the proliferation of keratinocytes of compounds of plant origin such as phloroglucinol.
- compositions according to the invention can comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA) and indole-3-butyric acid (IBA).
- auxin chosen from indolacetic acid (IAA), 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA) and indole-3-butyric acid (IBA).
- 2,4-dichlorophenoxyacetic acid (2,4-D), r /.- naphthaleneacetic acid (-NAA), ⁇ -naphthoxyacetic acid, indole ethanol, Idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol.
- a subject of the invention is also the use of the combination of vitamin C and at least one carotenoid and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes in a composition or for the preparation of a composition, the combination or the composition being intended to treat, preventively and / or curatively, the cutaneous signs of aging, to combat collagen degradations, to inhibit the expression of proteases of the extracellular matrix , to inhibit the expression of metalloproteinases, particularly metalloproteinase type 1, to treat skin disorders linked to menopause, to fight against fine lines and wrinkles, to fight against withered skin, to fight against soft skin, to fight against thinned skin, to fight against dull and / or dull skin, to fight against the lack of elasticity and / or tone of the skin, to fight against degradations of the skin following exposure to ultraviolet radiation.
- compositions according to the invention may comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), Indole-3-butyric acid (IBA).
- auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), Indole-3-butyric acid (IBA).
- 2,4-dichlorophenoxyacetic acid (2,4-D), u-naphthalene acetic acid ( ⁇ -NAA), fi-naphthoxyacetic acid, indole ethanol, idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol.
- the present invention further relates to a method of cosmetic treatment of the skin intended to stimulate the synthesis of collagen and / or fight against skin disorders linked to age and / or menopause and / or fight against thinning. of the dermis and / or combat the appearance of soft and / or wrinkled skin, characterized in that ('it is applied to the skin, on the hair, on the hair and / or on the mucous membranes or which is ingested a cosmetic composition comprising at least the combination of at least one carotenoid and vitamin C.
- the cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions. For example: application of creams, gels, serums, lotions, milks, shampoos or sunscreen compositions, on the skin or on the hair or on the hairs or also application of toothpaste on the gums and so preferable by oral administration of an oral solution, a syrup, a tablet, a capsule, a capsule or a nutrient food or a nutrient supplement.
- compositions illustrate the invention without limiting it in any way.
- proportions indicated are percentages by weight.
- composition 1 Soft capsules: Excipients: Soybean Oil 40 mg
- Composition 2 Care cream (oil in water emulsion, '
- Vitamin C 5.00% Glycrol stearate 2.00 '%
- Polysorbate 60 (Tween 60 'sold by ICI) 1.00%
- Composition 3 Lycopene 6% skin gel (Lycomato®) 0.0001%
- Composition 4 Care cream (oil-in-water emulsion)
- Lycopene 6% (Lycomato®) 0.01%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Utilisation de l'association d'au moins un caroténoïde et de vitamine C pour traiter les signes cutanés du vieillissementUse of the combination of at least one carotenoid and vitamin C to treat the skin signs of aging
L'invention se rapporte à l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à traiter les signes cutanés du vieillissement, en particulier la dégradation de la peau et/ou des muqueuses par l'inhibition de l'activité et/ou de l'expression des collagenases et par l'augmentation de la synthèse de collagène.The invention relates to the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to treat the cutaneous signs of aging. , in particular the degradation of the skin and / or mucous membranes by inhibiting the activity and / or expression of collagenases and by increasing the synthesis of collagen.
L'invention a également pour objet un procédé de traitement cosmétique de la peau et/ou des muqueuses.The invention also relates to a method of cosmetic treatment of the skin and / or mucous membranes.
Chez les mammifères en général, particulièrement chez l'homme, la peau est constituée de deux compartiments à savoir un compartiment en relation avec l'extérieur, l'épidémie, et n compartiment profond qui sert de soutien à l'épiderme, le derme.In mammals in general, particularly in humans, the skin consists of two compartments, namely a compartment in relation to the outside, the epidemic, and n deep compartment which serves to support the epidermis, the dermis.
L'épiderme est composé principalement de trois types de cellules qui sont les kératinocytes, très majoritaires, les mélanocytes et les cellules de Langerhans. Chacun de ces types cellulaires contribue par ses fonctions propres au rôle essentiel joué dans l'organisme par la peau.The epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
Le derme fournit à l'épiderme un support solide, C'est également son élément nourricier. Il est principalement constitué de fibroblastes et d'une matrice extracellulaire composée elle-même principalement de collagène, d'élastine et d'une substance, dite substance fondamentale, composants synthétisés par le fibroblaste. On y trouve aussi des leucocytes, des mastocytes ou encore des macrophages tîssulaires, il est également traversé par des vaisseaux sanguins et des fibres nerveuses. Dans une peau normale, c'est à dire non pathologique ni cicatricielle, le fibroblaste est à l'état quiescent. c'est à dire non prolifératif, peu actif d'un point de vue métabolique et non mobileThe dermis provides the epidermis with solid support. It is also its nourishing element. It mainly consists of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, known as the fundamental substance, components synthesized by the fibroblast. There are also leukocytes, mast cells or tissue macrophages, it is also crossed by blood vessels and nerve fibers. In normal skin, that is to say non-pathological or scarring, the fibroblast is in a quiescent state. ie non-proliferative, not very active from a metabolic point of view and not mobile
Les fibres de collagène assurent en grande partie la solidité du derme. Ces fibres sont constituées de fibrilles scellées les unes aux autres, formant ainsi plus de dix types de structures différentes. La solidité du derme est en grande partie due à l'enchevêtrement des fibres de collagène tassées les unes contre les autres en tous sens. Les fibres de collagène participent également à l'élasticité et surtout à la tonicité de la peau et/ou des muqueuses. Les fibres de collagène sont constamment renouvelées mais ce renouvellement diminue avec l'âge ce qui entraîne un amincissement du derme. Cet amincissement du derme est également dû à des causes pathologiques comme par exemple l'hypersécrétion d'hormones corticoïdes, certaines pathologies ou encore des carences vitaminïques. Il est également admis que des facteurs extrinsèques comme les rayons ultraviolets, le tabac ou certains traitements (Glucocorticoides, vitamine D et dérivés, par exemple) ont également un effet sur la peau et sur son taux de collagène.Collagen fibers largely ensure the solidity of the dermis. These fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures. The solidity of the dermis is largely due to the entanglement of collagen fibers packed against each other in all directions. Collagen fibers also participate in elasticity and especially in the tone of the skin and / or mucous membranes. The collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis. This thinning of the dermis is also due to pathological causes such as, for example, the hypersecretion of corticosteroid hormones, certain pathologies or vitamin deficiencies. It is also recognized that extrinsic factors such as ultraviolet rays, tobacco or certain treatments (Glucocorticoides, vitamin D and derivatives, for example) also have an effect on the skin and its collagen level.
Cependant, divers facteurs entraînent la dégradation du collagène, avec toutes les conséquences que l'on peut envisager sur la structure et/ou la fermeté de la peau et/ou des muqueuses.However, various factors cause the degradation of collagen, with all the consequences that can be envisaged on the structure and / or firmness of the skin and / or mucous membranes.
Bien que très résistantes, les fibres de collagène sont sensibles à certaines enzymes appelées collagenases. Une dégradation des fibres de collagène entraîne l'apparence de peau molle et ridée que l'on cherche depuis toujours à combattre, particulièrement chez l'être humain, préférant l'apparence d'une peau lisse et tendue.Although very resistant, collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that has always been sought to combat, particularly in humans, preferring the appearance of smooth and taut skin.
Les collagenases font partie d'une famille d'enzymes appelées métalloprotéînases (MMPs) qui sont elles-mêmes les membres d'une famille d'enzymes protéolytiques (endoprotéases) qui possèdent un atome de zinc coordonné à 3 résidus cystéîne et une méthîonïne dans leur site actif et qui dégradent les composants macromoléculaires de la matrice extracellulaîre et des lames basales à pH neutre (collagène, étastine, etc. . .). Très largement répandues dans le monde vivant, ces enzymes sont présentes, mais faiblement exprimées, dans des situations physiologiques normales comme ta croissance des organes et le renouvellement des tissus.Collagenases are part of a family of enzymes called metalloproteinases (MMPs) which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and basal laminae at neutral pH (collagen, etastin, etc.). Very widely distributed in the living world, these enzymes are present, but weakly expressed, in normal physiological situations such as your organ growth and tissue renewal.
Leur surexpression et leur actîvatîon sont cependant liées à de nombreux processus, parfois pathologiques, qui impliquent la destruction et le remodelage de la matrice. Cela entraîne soit une résorption non contrôlée de la matrice extracellulaire, soit inversement l'installation d'un état de fibrose.Their overexpression and their activity are however linked to many processes, sometimes pathological, which involve the destruction and reshaping of the matrix. This either leads to an uncontrolled resorption of the extracellular matrix, or conversely the establishment of a state of fibrosis.
La famille des métalloprotéînases est constituée de plusieurs groupes bien définis basés sur leurs ressemblances en terme de structure et de spécificité de substrat (voir Woessner J. F. , Faseb Journal, vol. 5 1991 , 2145). Parmi ces groupes, on peut citer les collagenases destinées à dégrader les collagènes fibrîllaires (MMP-1 ou collagénase interstitielle, MMP-8 ou collagénase de neutrophîle, MMP- 3 ou collagénase 3), les gélatinases qui dégradent le collagène de type IV ou toute forme de collagène dénaturé (MMP-2 ou gélatinase A (72 kDa), MMP-9 ou gélatinase B (92 kDa) ), les stromélysines (MMP-3) dont le large spectre d'activité s'adresse aux protéines de la matrice extracellulaire telles que les glycoprotéines (fibronectine, laminine), les protéoglycannes, etc., 5 ou encore les métalloprotéinases membranairesThe family of metalloproteinases consists of several well-defined groups based on their similarities in terms of structure and specificity of substrate (see Woessner JF, Faseb Journal, vol. 5 1991, 2145). Among these groups, mention may be made of collagenases intended for degrading fibrillar collagens (MMP-1 or interstitial collagenase, MMP-8 or neutrophile collagenase, MMP-3 or collagenase 3), gelatinases which degrade collagen type IV or any form of denatured collagen (MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)), stromelysins (MMP-3) whose broad spectrum of activity is address to proteins of the extracellular matrix such as glycoproteins (fibronectin, laminin), proteoglycans, etc., 5 or even membrane metalloproteinases
L'exposition prolongée aux rayonnements ultraviolets, particulièrement aux rayonnements ultraviolets de type A et/ou B, a pour effet une stimulation de l'expression des collagenases, particulièrement de la MMP-1 . C'est jà une des composantes du vieillissement cutané photo-induit. t oProlonged exposure to ultraviolet radiation, particularly type A and / or B ultraviolet radiation, stimulates the expression of collagenases, particularly MMP-1. This is one of the components of photo-induced skin aging. t o
Par ailleurs à la ménopause, les principales modifications concernant le derme sont une diminution du taux de collagène et de l'épaisseur dermique, Cela entraîne chez la femme ménopausée un amincissement de la peau et/ou des muqueuses. La femme ressent alors une sensation de "peau sèche" ou de peau 15 qui tire et l'on constate une accentuation des rides et ridules de surface. La peau présente un aspect rugueux à la palpatîon. Enfin la peau présente une souplesse diminuée.In addition to the menopause, the main modifications concerning the dermis are a reduction in the level of collagen and the dermal thickness, that involves in the menopausal woman a thinning of the skin and / or mucous membranes. The woman then feels a sensation of "dry skin" or of skin 15 which pulls and there is an accentuation of the wrinkles and fine lines on the surface. The skin has a rough appearance on the palpatîon. Finally, the skin has reduced flexibility.
On comprend alors à la lecture de ce qui précède l'importance du collagène dans 20 la structure des tissus, particulièrement de la peau et/ou des muqueuses, et l'importance qu'il y a à combattre sa dégradation pour ainsi lutter contre les signes cutanés du vieillissement, qu'il soit chronologique ou photo-induit, et ses conséquences, comme par exemple l'amincissement du derme et/ou la dégradation des fibres de collagène ce qui entraînent l'apparence de peau molle 25 et ridée,It is then understood on reading the foregoing the importance of collagen in the structure of tissues, particularly of the skin and / or mucous membranes, and the importance of combating its degradation so as to fight against cutaneous signs of aging, whether chronological or photo-induced, and its consequences, such as, for example, thinning of the dermis and / or degradation of the collagen fibers, which cause the appearance of soft and wrinkled skin,
Par signes cutanés du vieillissement on entend toutes modifications de l'aspect extérieur de la peau dues au vieillissement qu'il soit chronobîologique et/ou photo-induit, comme par exemple les rides et ridules, la peau flétrie, la peauThe expression “cutaneous signs of aging” means any modification of the external appearance of the skin due to aging, whether chronobiological and / or photo-induced, such as for example wrinkles and fine lines, withered skin, the skin
30 mole, la peau amincie, la peau terne et sans éclat, le manque d'élasticité et/ou de tonus de la peau, mais également toutes modifications internes de la peau qui ne se traduisent pas systématiquement par un aspect extéπeυi modifié, comme par exemple toutes dégradations internes de la peau, particulièrement des fibres de collagène. consécutives à une exposition aux rayonnements ultra-violets, qui30 mole, thinned skin, dull and dull skin, lack of elasticity and / or tone of the skin, but also all internal modifications of the skin which do not systematically result in a modified external appearance, such as by example all internal degradations of the skin, particularly of collagen fibers. following exposure to ultraviolet radiation, which
35 peuvent avoir comme conséquence l'amincissement du derme.35 can result in thinning of the dermis.
Un des buts de la présente invention est donc de pouvoir disposer d'un produit qui permette de traiter, chez les mammifères en général, particulièrement chez l'homme, de manière préventive et/ou curative, les signes cutanés du vieillissement qu'il soit chronobiologique ou photo-induit, particulièrement l'amincissement du derme et/ou la dégradation des fibres de collagène, par un effet stimulateur de la synthèse du collagène et/ou un effet inhibiteur des collagenases et si possible pas d'effets secondaires notables.One of the aims of the present invention is therefore to be able to have a product which makes it possible to treat, in mammals in general, particularly in man, preventively and / or curatively, the skin signs of aging, whether chronobiological or photo-induced, particularly thinning of the dermis and / or degradation of collagen fibers, by a stimulating effect on synthesis collagen and / or a collagenase inhibiting effect and if possible no significant side effects.
De manière surprenante, la Demanderesse a maintenant découvert que l'association d'au moins un caroténoïde et de vitamine C permet de traiter de manière préventive et/ou curative, les signes cutanés du vieillissement qu'il soit chronologique ou photo-induit, particulièrement l'amincissement du derme et/ou la dégradation des fibres de collagène, par un effet stimulateur de la synthèse du collagène et/ou Un effet inhibiteur des collagenases.Surprisingly, the Applicant has now discovered that the combination of at least one carotenoid and vitamin C makes it possible to treat, in a preventive and / or curative manner, the skin signs of aging, whether chronological or photo-induced, particularly thinning of the dermis and / or degradation of collagen fibers, by a stimulating effect on collagen synthesis and / or A collagenase inhibiting effect.
Une propriété remarquable de l'association de l'invention est qu'elle présente des effets dans des proportions plus importantes que celles raisonnablement attendues de la simple addition des effets de chacun de ces composants pris séparément.A remarkable property of the combination of the invention is that it has effects in greater proportions than those reasonably expected from the simple addition of the effects of each of these components taken separately.
Un avantage de cette propriété est de permettre une utilisation dans la composition de l'invention d'une quantité de chacun des produits inférieure à ce qu'il est généralement admis d'utiliser,An advantage of this property is to allow a use in the composition of the invention of a quantity of each of the products less than what is generally accepted to use,
A la connaissance de la demanderesse l'activité stimulatrice sur la synthèse du collagène et l'activité inhibitrîce sur l'expression et/ou l'activité des collagenases de l'association d'au moins un caroténoïde et de vitamine C n'ont jamais été décrites.To the knowledge of the applicant, the stimulatory activity on the synthesis of collagen and the inhibitory activity on the expression and / or the activity of collagenases from the combination of at least one carotenoid and vitamin C have never been described.
Ainsi, l'invention a pour premier objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à traiter les signes cutanés du vieillissement.Thus, the first object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to treat the signs skin of aging.
L'invention a pour second objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre les dégradations du collagène.A second object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to combat degradation of the collagen.
L'invention a pour troisième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à inhiber l'expression des protéases de la matrice extracellulaire, particulièrement des métalloprotéînases et encore plus particulièrement de la métalloprotéinase de type 1 .A third object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to inhibit the expression of the proteases of the extracellular matrix, particularly metalloproteinases and even more particularly metalloproteinase type 1.
L'invention a pour quatrième objet l'utilisation de l'association dans Une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à traiter les atteintes cutanées liées au vieillissement, notamment aux atteintes cutanées de la ménopause,A fourth object of the invention is the use of the combination in a composition or for the preparation of a composition of the combination of at least one carotenoid and vitamin C, the combination or the composition being intended to treat skin disorders linked to aging, in particular skin disorders of menopause,
L'invention a pour cinquième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre les rides et ridules.A fifth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to combat wrinkles and wrinkles.
L'invention a pour sixième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre la peau flétrie.The sixth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to fight against withered skin .
L'invention a pour septième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre la peau molle.The seventh subject of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended for combating soft skin .
L'invention a pour huitième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre la peau amincie.The eighth object of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended to fight against thinned skin. .
L'invention a pour neuvième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre la peau terne et sans éclat.The ninth subject of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of vitamin C, the association or the composition being intended for combating dull skin and dull.
L'invention a pour dixième objet l'utilisation dans une composition ou pour la préparation d'une composition de l'association d'au moins un caroténoïde et de vitamine C, l'association ou la composition étant destinées à lutter contre le manque d'élasticité et/ou de tonus de la peau,A tenth subject of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of vitamin C, the combination or the composition being intended to combat the lack of elasticity and / or tone of the skin,
Quelle que soit l'utilisation envisagée de l'invention, celle-ci peut être de manière préventive et/ou curative à l'atteinte qu'elle vise à traiter.Whatever the intended use of the invention, it can be preventive and / or curative to the harm it aims to treat.
Il est bien évident que l'invention s'adresse aux mammifères en général et particulièrement aux êtres humains.It is obvious that the invention is intended for mammals in general and particularly for human beings.
Par caroténoïde, on entend selon l'invention aussi bien un caroténoïde à activité provitaminîque A, qu'un caroténoïde sans activité provitamimque A.By carotenoid is meant according to the invention both a carotenoid with provitamin A activity, and a carotenoid without provitamin A activity.
Bien entendu selon l'invention, le caroténoïde peut être un mélange de caroténoides à activité provitamînique A et de caroténoides sans activité provitamîniqiie A. Ce mélange peut être en toute proportion.Of course according to the invention, the carotenoid can be a mixture of carotenoids with provitamin A activity and carotenoids without provitamin A activity. This mixture can be in any proportion.
Selon l'invention, le caroténoïde à activité provitaminîque A peut être un mélange de caroténoïdes à activité provitaminîque A. Ce mélange peut être en toute proportion. Parmi les caroténoïdes à activité provîtaminique A, on peut citer à titre d'exemple le β-carotène ou l'α-carotène,According to the invention, the carotenoid with provitamin A activity can be a mixture of carotenoids with provitamin A activity. This mixture can be in any proportion. Among the carotenoids with provitamin A activity, there may be mentioned by way of example β-carotene or α-carotene,
Préférentieilement selon l'invention on utilise le β-carotènePreferably according to the invention, β-carotene is used.
Selon l'invention, le caroténoïde sans activité provitamînique A peut être un mélange de caroténoides sans activité provitamînique A, Ce mélange peut être en toute proportion, Parmi les caroténoïdes sans activité provitaminîque A, on peut citer à titre d'exemple te zéaxanthine. la cryptoxanthîne, la lutéine ou le lycopène. Préférentieilement selon l'invention on utilise le lycopène.According to the invention, the carotenoid without provitamin A activity can be a mixture of carotenoids without provitamin A activity. This mixture can be in any proportion. Among the carotenoids without provitamin A activity, mention may be made, for example, of zeaxanthin. cryptoxanthine, lutein or lycopene. Preferably according to the invention, lycopene is used.
Préférentieilement selon l'invention on utilise un caroténoïde sans activité provitamînique A et encore plus préférentieilement le lycopène.Preferably according to the invention, a carotenoid without provitamin A activity is used and even more preferably lycopene.
Le lycopène est un pigment naturel que l'on trouve dans les fruits mûrs, particulièrement dans la tomate. Il appartient à la famille des caroténoïdes et sa structure est proche de celle du β-carotène. Le rôle du lycopène dans la maturation des fruits est connu dans l'art antérieur Le lycopène est utilisé dans des compositions à activité bronzante pour son rôle sur la synthèse de mélanine (WO 97/47278), dans des compositions destinées au traitement de la chevelure et/ou de l'acné pour son activité sur les 5 -réductases (JP-2940964) ou encore comme agent anti-radîcalaire (JP-A- 8-283136.Lycopene is a natural pigment found in ripe fruit, especially in tomatoes. It belongs to the carotenoid family and its structure is close to that of β-carotene. The role of lycopene in the ripening of fruits is known in the prior art Lycopene is used in compositions with bronzing activity for its role on the synthesis of melanin (WO 97/47278), in compositions intended for the treatment of the hair and / or acne for its activity on 5-reductases ( JP-2940964) or also as an anti-radical agent (JP-A- 8-283136.
Le lycopène peut être sous forme chimique cis ou trans.Lycopene can be in cis or trans chemical form.
Le caroténoïde utilisé selon l'invention peut être d'origine naturelle ou synthétique. Par origine naturelle, on entend le caroténoïde, à l'état pur ou en solution quelle qu'en soit sa concentration dans ladite solution, obtenu à partir d'un élément naturel.The carotenoid used according to the invention can be of natural or synthetic origin. By natural origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element.
Selon un mode préférentiel de l'invention, on utilise un extrait riche en lycopène, comme par exemple un extrait de tomate. Par origine synthétique, on entend le caroténoïde, à l'état pur ou en solution quelle qu'en soît sa concentration dans ladite solution, obtenu par synthèse chimique.According to a preferred embodiment of the invention, an extract rich in lycopene is used, such as for example a tomato extract. By synthetic origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained by chemical synthesis.
Lorsque le caroténoïde est d'origine naturelle, il peut être obtenu à partir de matériel végétal issu de plante entière cultivée in vivo ou issu de culture in vitro.When the carotenoid is of natural origin, it can be obtained from plant material from a whole plant grown in vivo or from in vitro culture.
Par culture in vivo on entend toute culture de type classique c'est à dire en sol à l'air libre ou en serre, ou encore hors sol.The term “in vivo culture” means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
Par culture in vitro, on entend l'ensemble des techniques connues de l'homme du métier qui permet de manière artificielle l'obtention d'un végétai ou d'une partie d'un végétai. La pression de sélection imposée par les conditions physico- chimiques lors de la croissance des cellules végétales in vitro permet d'obtenir un matériel végétal standardisé et disponible tout au long de l'année contrairement aux plantes cultivées in vivoThe term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
Préférentieilement selon l'invention, on utilise un végétal issu de culture in vivoPreferably according to the invention, a plant derived from culture in vivo is used.
Toute méthode d'extraction connue de l'homme du métier peut être utilisée pour préparer le caroténofde utilisé selon l'invention.Any extraction method known to those skilled in the art can be used to prepare the carotenofde used according to the invention.
Le caroténoïde peut être en solution alcoolique, notamment éthanolîque. Le caroténoïde peut également être en solution lipidique (huile) ou lipoalcoolique.The carotenoid can be in alcoholic solution, in particular ethanolic. The carotenoid can also be in lipid (oil) or lipoalcoholic solution.
A titre d'exemple, selon l'invention on utilise un extrait de tomate riche en lycopène, préparé par la société Métaphar, commercialisé sous la dénomination LycOMato® constitué d'un extrait d'oléorésine (phase grasse) contenant 6% de lycopène pur.By way of example, according to the invention, a tomato extract rich in lycopene is used, prepared by the company Métaphar, marketed under the name LycOMato® consisting of an oleoresin extract (fatty phase) containing 6% of pure lycopene. .
On peut également utiliser selon l'invention toute préparation contenant du lycopène ayant pour objectif d'améliorer la biodîsponibilité de ce dernier.It is also possible to use, according to the invention, any preparation containing lycopene having the objective of improving the bioavailability of the latter.
La quantité de caroténoïde utilisable selon l'invention est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.The amount of carotenoid that can be used according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
Pour donner un ordre de grandeur, dans la composition selon l'invention le caroténoïde à l'état pur est en une quantité représentant de 10"1l 2% à 20% du poids total de la composition et préférentieilement en une quantité représentant de 10'10% à 10% du poids total de la composition.To give an order of magnitude, in the composition according to the invention the carotenoid in the pure state is in an amount representing from 10 "11 to 2 % to 20% of the total weight of the composition and preferably in an amount representing from 10 ' 10 % to 10% of the total weight of the composition.
Bien entendu l'homme du métier, s'il utilise le caroténoïde sous la forme d'une solution, un extrait végétal par exemple, sait ajuster la quantité de solution qu'il Utilise dans sa composition afin que la quantité finale de caroténoïde dans la composition soit en accord avec les quantités utilisables précédemment définies.Of course the skilled person, if he uses the carotenoid in the form of a solution, a plant extract for example, knows how to adjust the amount of solution he uses in its composition so that the final amount of carotenoid in the composition is in agreement with the usable quantities previously defined.
La vitamine C (ou acide ascorbique) est connue pour stimuler la synthèse de collagène, en empêchant, en tant que co-facteur, l'auto-inactivation des enzymes lysine- et proline-hydroxylases et en augmentant la synthèse des ARNrn de procollagènes L'acide ascorbique (ou vitamine C) est également connu pour stimuler la synthèse de l'élastîne de la peau. On peut citer à cet égard les brevetsVitamin C (or ascorbic acid) is known to stimulate the synthesis of collagen, by preventing, as a co-factor, the auto-inactivation of the enzymes lysine- and proline-hydroxylases and by increasing the synthesis of the rRNA of procollagènes L ascorbic acid (or vitamin C) is also known to stimulate the synthesis of elastin of the skin. We can cite in this respect the patents
US 5801 192. US 4983382 et EP 0717983. On peut également citer un article intitulé «Pola to încorporate vîtamin C in new cosmetics tîne for skin cars duUS 5801 192. US 4983382 and EP 0717983. We can also cite an article entitled "Pola to încorporate vîtamin C in new cosmetics tîne for skin cars du
Japan Economie Journal du 5 juin 1 984 (page 1 5). Ainsi, il a été décrit que l'acide ascorbique utilisé dans les compositions cosmétiques permet de traiter notamment tes rides (Fragrance Journal, Vol. 8, n°6 (45) (1980) pp3δ-43,Japan Economie Journal of June 5, 1,984 (page 1 5). Thus, it has been described that the ascorbic acid used in cosmetic compositions makes it possible to treat in particular your wrinkles (Fragrance Journal, Vol. 8, n ° 6 (45) (1980) pp3δ- 4 3,
« Cosmetîc and vitamin - action and safety to dermatology »),"Cosmetîc and vitamin - action and safety to dermatology"),
Selon l'invention l'acide ascorbique et/ou ses analogues peuvent être utilisés seuls ou en mélanges de toute nature et toute proportion et peuvent être d'origine naturelle ou synthétique. L'acide ascorbique est généralement sous forme L, car c'est plus particulièrement sous cette forme qu'il est retrouvé dans le monde végétal.According to the invention ascorbic acid and / or its analogs can be used alone or in mixtures of any kind and any proportion and can be of natural or synthetic origin. Ascorbic acid is generally in L form, because it is more particularly in this form that it is found in the plant world.
La quantité de vitamine C utilisable selon l'invention est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.The amount of vitamin C usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
Pour donner un ordre de grandeur, dans la composition de l'invention Ja vitamine C à l'état pur peut-être en une quantité représentant de 10"1l0% à 20% du poids total de la composition et préférentieilement en une quantité représentant de 10" 8% à 10% du poids total de la composition.To give an order of magnitude, in the composition of the invention, vitamin C in the pure state, perhaps in an amount representing from 10 " 10 10% to 20% of the total weight of the composition and preferably in an amount representing 10 " 8 % to 10% of the total weight of the composition.
Bien entendu, si la vitamine C est présente sous la forme d'une solution, par exemple un extrait de plante, l'homme du métier saura ajuster la quantité de cette solution dans la composition selon l'invention, de façon à obtenir les gammes de concentrations en vitamine C ci-dessus décrites.Of course, if vitamin C is present in the form of a solution, for example a plant extract, the skilled person will be able to adjust the amount of this solution in the composition according to the invention, so as to obtain the ranges of vitamin C concentrations described above.
La composition de l'invention peut être sous toutes formes gaiénîques imaginables, adaptées aussi bien à une application topique sur la peau et/ou les muqueuses et/ou les cheveux et/ou tes poils qu'à une administration par la voie orale.The composition of the invention can be in any imaginable form, suitable both for topical application to the skin and / or mucous membranes and / or the hair and / or your hair as for administration by the oral route.
De manière préférentielle, la composition de" l'invention est destinée à une administration par la voie orale.Preferably, the composition of " the invention is intended for administration by the oral route.
La composition de l'invention peut être une composition cosmétique ou dermatologique. Préférentieilement selon l'invention, la composition est une composition cosmétique, La composition est une composition cosmétique car elle est destinée à améliorer l'aspect cutané général de l'individu qui en fait usage. Très préférentieilement la composition de l'invention est une composition cosmétique destinée à une administration par la voie orale,The composition of the invention can be a cosmetic or dermatological composition. Preferably according to the invention, the composition is a cosmetic composition. The composition is a cosmetic composition because it is intended to improve the general cutaneous appearance of the individual who uses it. Very preferably the composition of the invention is a cosmetic composition intended for administration by the oral route,
Pour une administration par la voie orale, la composition de l'invention peut se présenter sous toutes les formes adaptées, particulièrement sous forme d'une solution buvable, d'un sirop, d'un comprimé, d'une dragée, d'une gélule ou encore d'une capsule ou encore un aliment nutritîonnel ou d'un complément nutrîtîonnel. Ladite composition peut comprendre en outre au moins un excipient approprié adapté à l'administration orale,For administration by the oral route, the composition of the invention can be in any suitable form, particularly in the form of an oral solution, a syrup, a tablet, a dragee, a capsule or a capsule or a nutritional food or a nutritional supplement. Said composition can also comprise at least one suitable excipient suitable for oral administration,
Pour une administration par application topique sur la peau, les cheveux, les poils et/ou les muqueuses, la composition selon l'invention comprend bien évidemment un support cosmétiquement acceptable, c'est à dire un support compatible avec la peau, les muqueuses, les ongles, les cheveux, les poils et peut se présenter sous toutes les formes galénîques normalement utilisées pour une application topique, notamment sous forme d'une solution aqueuse, hydroalcoolique ou huileuse, d'une émulsion huile-dans-eau ou eau-dans-huile ou multiple, d'un gel aqueux ou huileux, d'un produit anhydre liquide, pâteux ou solide, d'une dispersion d'huile dans une phase aqueuse à l'aide de sphérules, ces sphérules pouvant être des nanoparticules polymériques telles que les nanosphères et les nanocapsules ou mieux des vésicules lipidiques de type ionique et/ou non-ionique.For administration by topical application to the skin, hair, body hair and / or mucous membranes, the composition according to the invention obviously comprises a cosmetically acceptable carrier, that is to say a carrier compatible with the skin, the mucous membranes, the nails, the hair, the hairs and can be in all the galenic forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, of an oil-in-water or water-in emulsion oil or multiple, of an aqueous or oily gel, of a liquid, pasty or solid anhydrous product, of an oil dispersion in an aqueous phase using spherules, these spherules possibly being polymeric nanoparticles such than nanospheres and nanocapsules or better lipid vesicles of ionic and / or nonionic type.
Cette composition peut être plus ou moins fluide et avoir l'aspect d'une crème blanche ou colorée, d'une pommade, d'un lait, d'une lotion, d'un sérum, d'une pâte, d'une mousse. Elle peut éventuellement être appliquée sur la peau sous forme d'aérosol. Elle peut également se présenter sous forme solide, et par exemple sous forme de stick. Elle peut être utilisée comme produit de soin, comme produit de nettoyage, comme produit de maquillage ou encore comme simple produit déodorant,This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product, as a cleaning product, as a makeup product or even as a simple deodorant product,
De façon connue, la composition de l'invention peut contenir les adjuvants habituels dans les domaines cosmétiques et dermatologique, tels que les gélifiants hydrophiles ou lîpophiles. les actifs hydrophiles ou lipophiles, les conservateurs, les antioxydants, les solvants, les parfums, les charges, les filtres, les pigments, les agents chélatetirs, les absorbeurs d'odeur et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement Utilisées dans les domaines considérés et par exemple de 0,01 % à 20% du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse, dans les vésicules lipidiques et/ou dans les nanoparticulesIn a known manner, the composition of the invention may contain the adjuvants customary in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents. hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, chelating agents, odor absorbers and coloring matters. The amounts of these various adjuvants are those conventionally used in the fields considered and for example from 0.01% to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.
Lorsque la composition de l'invention est une émulsion, la proportion de la phase grasse peut aller de 5% à 80% en poids, et de préférence de 5% à 50% du poids total de la composition. Les huiles, les émuisîonnants et les coémulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine considéré. L'émulsionnant et le coémulsionnant sont présents, dans la composition, en une proportion allant de 0,3% à 30% en poids, et de préférence de 0,5% à 20% du poids total de la composition.When the composition of the invention is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% of the total weight of the composition. Oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% of the total weight of the composition.
Comme huiles utilisables dans l'invention, on peut citer les huiles minérales, les huiles d'origine végétale (huile d'abricot, huile de tournesol), les huiles d'origine animale, les huiles de synthèse, les huiles silîconées et les huiles fluorées (perfluoropolyéthers). On peut aussi utiliser comme matières grasses des alcools gras (alcool cétylique), des acides gras, des cires (cire d'abeilles).As oils which can be used in the invention, mention may be made of mineral oils, oils of vegetable origin (apricot oil, sunflower oil), oils of animal origin, synthetic oils, silicone oils and oils. fluorinated (perfluoropolyethers). Fatty alcohols (cetyl alcohol), fatty acids, waxes (beeswax) can also be used as fats.
Comme émulsîonnants et coémulslonnants utilisables dans l'invention, on peut citer par exemple les esters d'acide gras et de polyéthylène glycol tels que le stéarate de PEG-40, le stéarate de PEG-100, les esters d'acide gras et de polyol tels que le stéarate de glycéryle et le trîstéarate de sorbitane.As emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitan tristearate.
Comme gélifiants hydrophiles, on peut citer en particulier les polymères carboxyvinylîques (carbomer). les copolymères acryliques tels que les copolymères d'acrylates/alkylacrylates, les polyacrylamldes, les polysaccharides, les gommes naturelles et les argiles, et, comme gélifiants lipophiles, on peut citer les argiles modifiées comme les bentones, les sels métalliques d'acides gras, la silice hydrophobe et les polyéthylènes,As hydrophilic gelling agents, mention may in particular be made of carboxyvinyl polymers (carbomers). acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes,
La composition peut contenir d'autres actifs hydrophiles comme les protéines ou les hydrolysats de protéine, les acides aminés, les polyols, l'urée, l'allantoïne, les sucres et les dérivés de sucre, les extraits végétaux et les hydroxy-acides.The composition can contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, plant extracts and hydroxy acids.
Comme actifs lipophiles. on peut utiliser le rétinol (vitamine A) et ses dérivés, le to ophérol (vitamine E) et ses dérivés, les acides gras essentiels, les cérainides, les huiles essentielles, l'acide salicylique et ses dérivés ou encore les vitamines B 1 , B6 et /oU B12.As lipophilic active ingredients. retinol (vitamin A) and its derivatives, to opherol (vitamin E) and its derivatives, essential fatty acids, cerainides, essential oils, salicylic acid and its derivatives or even vitamins B 1 can be used, B6 and / or B12.
Il est également possible d'utiliser dans la composition de l'invention au moins un isoflavonoïde, éventuellement un extrait végétal riche en isoflavonoïdes. comme par exemple l'extrait de soja (Glycîna max) disponible auprès de Archer Daniels Midland Company sous la dénomination Novasoy©. Une composition préférée de l'invention comprend entres autres ingrédients l'association d'au moins un caroténoïde et de vitamine C, un extrait végétal riche en isoflavonoïdes et de l' -tocophérol.It is also possible to use in the composition of the invention at least one isoflavonoid, optionally a plant extract rich in isoflavonoids. such as for example the soy extract (Glycîna max) available from Archer Daniels Midland Company under the name Novasoy ©. A preferred composition of the invention comprises, among other ingredients, the combination of at least one carotenoid and vitamin C, a plant extract rich in isoflavonoids and -tocopherol.
Encore plus préférentieilement, la composition de l'Invention comprend entre autres ingrédients l'association de β-carotène et de vitamine C, de l'extrait de soja (Novasoy® de la société Archer Daniels Midland Company), et de l'acétate d'α-tocophérol.Even more preferably, the composition of the invention comprises, among other ingredients, the combination of β-carotene and vitamin C, soy extract (Novasoy® from the company Archer Daniels Midland Company), and acetate d 'α-tocopherol.
Il est également possible d'utiliser en outre dans la composition de l'invention des composés choisis parmiIt is also possible to use, in addition, in the composition of the invention, compounds chosen from
- les oligo-éléments ;- trace elements;
- les hormones végétales ;- plant hormones;
- les agents antagonistes de calcium, comme le vérapamil et le Diltiazem ;- calcium antagonists, such as verapamil and Diltiazem;
- des capteurs de radicaux OH, tels que le diméthylstilfoxyde ;- OH radical sensors, such as dimethylstilfoxide;
- des ouvreurs de canaux chlore ;- chlorine channel openers;
- des extraits de végétaux des extraits de micro-organismes dont en particulier des extraits bactériens comme ceux de bactéries filamenteuses non photosynthétîques,- plant extracts, extracts of micro-organisms including in particular bacterial extracts such as those of non-photosynthetic filamentous bacteria,
A la liste ci-dessus, d'autres composés peuvent également être rajoutés, à savoir par exemple tes ouvreurs de canaux potassiques tels que le dîazoxyde et le mtnoxidil. la spiroxazone, des phospholipides comme la lécithîne, les acides lïnoléique et linolénique, l'acide salicylique et ses dérivés décrits dans le brevet français FR 2 581 542, comme les dérivés de l'acide salicylique porteurs d'un groupement alcanoyle ayant de 2 à 12 atomes de carbone en position 5 du cycle benzénique, des acides hydroxycarboxyliques ou cétocarboxyliques et leurs esters, des lactones et leurs sels correspondants, l'anthraline, des caroténoïdes, les acides eîcosatétraénoïque et eîcosatriénoïque ou leur s esters et amîdes, la vitamine D et ses dérivés.To the list above, other compounds can also be added, namely for example your potassium channel openers such as diazoxide and mtnoxidil. spiroxazone, phospholipids such as lecithin, linoleic and linolenic acids, salicylic acid and its derivatives described in French patent FR 2 581 542, such as salicylic acid derivatives carrying an alkanoyl group having from 2 to 12 carbon atoms in position 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and their esters, lactones and their corresponding salts, anthralin, carotenoids, eicosatetraenoic and eicosatrienoic acids or their esters and amides, vitamin D and its derivatives.
Selon l'invention, on peut, entre autres, ajouter à la composition de l'invention d'autres agents actifs destinés notamment à la pr évention et/ou au traitement des affections cutanées. Parmi ces agents actifs on peut citer à titre d'exempte : - les agents modulant la différenciation et/ou la prolifération et/ou la pigmentation cutanée tels que l'acîde rétînoïque et ses isomères, le rétinol et ses esters, la vitamine D et ses dérivés, les œstrogènes tels que l'œstradlol, l'acîde kojîque ou l'hydroquinone ; - les antibactériens tels que le phosphate de clindamycine, i'érythromycine ou les antibiotiques de la classe des tétracyclines ;According to the invention, can be, among others, added to the composition of the invention with other active agents intended in particular for pr évention and / or treatment of skin disorders. Among these active agents, mention may be made, by way of example: - agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradlol, kojic acid or hydroquinone; - Antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class;
- les agents modulant l'adhésion bactérienne sur la peau et /ou les muqueuses tels que le miel, notamment le miel d'acacias et certains dérivés de sucres ; - les antiparasitaîres, en particulier le métronidazole, le crotamîton ou les pyréthrînoïdes ;- agents modulating bacterial adhesion to the skin and / or mucous membranes such as honey, in particular acacia honey and certain sugar derivatives; - antiparasitic agents, in particular metronidazole, crotamion or pyrethroids;
- les antifongiques, en particulier les composés appartenant à la classe des îmidazoles tels que l'éconazole, te kétoconazole ou le mîconazole oujeurs sels, les composés polyènes, tels que Pamphotéricîne B, les composés de la famille des allylamînes, tels que la terbinafine, ou encore i'octopîrox ;antifungals, in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconcon or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or even the octoprox;
- les agents antiviraux tels que l'acyclovir ;- antiviral agents such as acyclovir;
- les agents anti-inflammatoires stéroïdiens, tels que l'hydrocortisone, le valérate de bètaméthasone ou le propionate de clobétasol, ou les agents antiinflammatoires non-stéroïdîens tels que l'ibuprofène et ses sels, le diclofénac et ses sels, l'acide acétylsalicylique, l'acétaminophène ou l'acide giycyrrhétinïque ;- steroidal anti-inflammatory agents, such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid , acetaminophen or giycyrrhetinic acid;
- les agents anesthésiques tels que le chlorhydrate de lidocaïne et ses dérivés ;- anesthetic agents such as lidocaine hydrochloride and its derivatives;
- les agents antiprurigineux comme la thénaldîne, la triméprazine ou la cyproheptadîne ;- antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;
- les agents kératolytiques tels que les acides alpha- et bêta- hydroxycarboxyliques ou bêta-cétocarboxyliques, leurs sels, amides ou esters et plus particulièrement tes hydroxy-acides tels que l'acîde glycolîque, l'acide lactique, l'acide salicylique, l'acide citrique et dé manière générale les acides de fruits, et l'acide n-octanoyl-5-sa cylique ;- keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and generally fruit acids, and n-octanoyl-5-sa cyclic acid;
- les agents anti-radicaux libres, tels que les superoxyde clismutases, certains chélatants de métaux ou l'acide ascorbique et ses esters ,- anti-free radical agents, such as superoxide clismutases, certain metal chelators or ascorbic acid and its esters,
- les anti-séborrhéiques tels que la progestérone ,- anti-seborrheic drugs such as progesterone,
- les antipelliculaires comme I'octopîrox ou la pyrithione de zinc ;- anti-dandruff agents such as octopirox or zinc pyrithione;
- les antiacnéiques comme l'acide rètînoique ou le peroxyde de benzoyle.- anti-acne drugs such as retinic acid or benzoyl peroxide.
- des substances telles que les antagonistes de substance P, de CGRP ou de bradykmine ou les inhibiteurs de MO synthase ou encore les inhibiteurs de canaux sodîques, composés décrits comme étant actifs dans le traitement des peaux sensibles et comme présentant des effets anti-irritants, en particulier vis-à- vis de composés irritants éventuellement présents dans les compositions.- substances such as substance P, CGRP or bradykmine antagonists or MO synthase inhibitors or sodium channel inhibitors, compounds described as being active in the treatment of sensitive skin and as having anti-irritant effects, in particular with regard to irritant compounds possibly present in the compositions.
Comme actifs, on peut utiliser notamment les hydratants tels que les polyols (par exemple la glycérine), les vitamines (par exemple le D-panthènol), les agents anti-inflammatoires, les agents apaisants (allantoïne, eau de bleuet), les filtres UVA et UVB, les agents matîfiants (par exemple les polydiméthylorganosiloxanes partiellement réticulés vendus sous le nom KSG® par Shin Etsu) et leurs mélanges.As active agents, moisturizers such as polyols (for example glycerin), vitamins (for example D-panthenol), anti-inflammatory agents, soothing agents (allantoin, blueberry water), filters can be used UVA and UVB, matting agents (for example polydimethylorganosiloxanes partially crosslinked sold under the name KSG® by Shin Etsu) and their mixtures.
On peut aussi ajouter des actifs antirides, et notamment des produits tenseurs tels que les protéines végétales et leurs hydrolysats, en particulier l'extrait de protéines de soja vendu sous le nom d'Eleseryl® par la société LSN ou le dérivé d'avoine vendu sous la dénomination Reductine® par la société Silab.Anti-wrinkle active agents can also be added, and in particular tensing products such as vegetable proteins and their hydrolysates, in particular the soy protein extract sold under the name Eleseryl® by the company LSN or the oat derivative sold. under the name Reductine® by the company Silab.
La peau étant constituée de bien d'autres composants que le collagène et les fibroblastes, il s'avère intéressant, lorsque l'on utilise l'association de l'invention, de favoriser en même temps la synthèse de ces autres composants comme par exemple les lipides et/ou de favoriser la prolifération d'autres composantes cellulaires comme par exemple les kératinocytesSince the skin is made up of many other components than collagen and fibroblasts, it turns out to be advantageous, when using the combination of the invention, to promote at the same time the synthesis of these other components such as for example lipids and / or promote the proliferation of other cellular components such as, for example, keratinocytes
Ainsi, l'invention a pour objet une composition cosmétique comprenant dans Un milieu cosmétîquement acceptable l'association d'au moins un caroténoïde et de vitamine C et au moins un autre produit stimulant la synthèse des lipides et/ou la prolifération des kératinocytes. Ladite composition peut être destinée à une utilisation dans le domaine cosmétique ou dermatologique, préférentieilement dans le domaine cosmétique.Thus, the subject of the invention is a cosmetic composition comprising, in a cosmetically acceptable medium, the combination of at least one carotenoid and vitamin C and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes. Said composition can be intended for use in the cosmetic or dermatological field, preferably in the cosmetic field.
Dans cette composition, la vitamine C et le caroténoïde peuvent être tels que décrit précédemment dans le texteIn this composition, vitamin C and the carotenoid can be as described previously in the text
On peut citer comme produit stimulant la synthèse des lipides, les hormones végétales, comme les auxines, ou des composés d'origine végétale, comme l'acîde cîrinamiqtie et comme produit stimulant la prolifération des kératinocytes des composés d'origine végétale, comme le phloroglucinolMention may be made, as product stimulating the synthesis of lipids, of plant hormones, such as auxins, or of compounds of plant origin, such as kinetic acid, and as product stimulating the proliferation of keratinocytes of compounds of plant origin, such as phloroglucinol.
Ainsi, les compositions selon l'invention peuvent compr endre en plus de l'association de l'invention, de l'acide cinnamique ou ses dérivés et/ou une hormone végétale, particulièrement une auxîne choisie parmi l'acide indolacètîque (IAA), l'acide 4-chloroîndole-3-acétιque (4-CI-IAA), l'acide phénylacêtîque (PAA) l'acîde ιndole-3-butyrîque (IBA). l'acide 2,4- dichlorophenoxyacétîque (2,4-D), l'acide r/.-naphtalèneacéttqυe ( -NAA), l'acîde β-naphtoxyacétîque, l'indole éthanol, l'Idole acétalcléhyde et l'indole acétonîtrîte et/ou un composé végétal comme le phloroglucinol. L'invention a aussi pour objet l'utilisation de l'association de vitamine C et d'au moins un caroténoïde et d'au moins un autre produit stimulant la synthèse des lipides et/ou la prolifération des kératinocytes dans une composition ou pour la préparation d'une composition, l'association ou la composition étant destinées à traiter, de manière préventive et/ou curative, les signes cutanés du vieillissement, à lutter contre les dégradations du collagène, à inhiber l'expression des protéases de la matrice extracellulaîre, à inhiber l'expression des métalloprotéinases, particulièrement la métalloprotéînase de type 1 , à traiter les atteintes cutanées liées à la ménopause, à lutter contre les rides et ridules, à lutter contre la peau flétrie, à lutter contre la peau molle, à lutter contre la peau amincie, à lutter contre la peau terne et/ou sans éclat, à lutter contre le manque d'élasticité et/ou de tonus de la peau, à lutter contre les dégradations internes de la peau consécutives à une exposition aux rayonnements ultra-violets.Thus, the compositions according to the invention can comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA) and indole-3-butyric acid (IBA). 2,4-dichlorophenoxyacetic acid (2,4-D), r /.- naphthaleneacetic acid (-NAA), β-naphthoxyacetic acid, indole ethanol, Idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol. A subject of the invention is also the use of the combination of vitamin C and at least one carotenoid and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes in a composition or for the preparation of a composition, the combination or the composition being intended to treat, preventively and / or curatively, the cutaneous signs of aging, to combat collagen degradations, to inhibit the expression of proteases of the extracellular matrix , to inhibit the expression of metalloproteinases, particularly metalloproteinase type 1, to treat skin disorders linked to menopause, to fight against fine lines and wrinkles, to fight against withered skin, to fight against soft skin, to fight against thinned skin, to fight against dull and / or dull skin, to fight against the lack of elasticity and / or tone of the skin, to fight against degradations of the skin following exposure to ultraviolet radiation.
A cet égard on peut citer comme produit stimulant la synthèse des lipides les hormones végétales, comme les auxines, ou des composés d'origine végétale, comme l'acide cînnalmique et comme produit stimulant la prolifération des kératinocytes des composés d'origine végétale, comme le phloroglucinol.In this respect, mention may be made, as product stimulating the synthesis of lipids, of plant hormones, such as auxins, or of compounds of vegetable origin, such as cinnalmic acid, and as product stimulating the proliferation of keratinocytes of compounds of vegetable origin, phloroglucinol.
Ainsi, tes compositions selon l'invention peuvent comprendre en plus de l'association de l'invention, de l'acide cïnnamique ou ses dérivés et/ou une hormone végétale, particulièrement une auxine choisie parmi l'acide indolacétique (IAA), l'acide 4-chloroindole-3-acétîque (4-CI-IAA), l'acide phénylacétique (PAA), l'acîde Indole-3-butyrique (IBA). l'acide 2,4- dichlorophenoxyacétique (2,4-D), l'acide u-naphtalèneacétîque (α-NAA), l'acide fi-naphtoxyacéiîque, l'indole éthanol, l'idole acétaldéhyde et l'indole acétonitrîle et/ou un composé végétal comme le phloroglucinol.Thus, your compositions according to the invention may comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), Indole-3-butyric acid (IBA). 2,4-dichlorophenoxyacetic acid (2,4-D), u-naphthalene acetic acid (α-NAA), fi-naphthoxyacetic acid, indole ethanol, idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol.
La présente invention a en outre pour objet un procédé de traitement cosmétique de la peau destiné à stimuler la synthèse du collagène et/ou lutter contre les atteintes cutanées liées à l'âge et/ou à la ménopause et/ou lutter contre l'amincissement du derme et/ou combattre l'apparence de la peau molle et/ou ridée, caractérisé par le fait que ('on applique sur la peau, sur les cheveux, sur les poils et/ou sur les muqueuses ou que l'on ingère une composition cosmétique comprenant au moins l'association d'au moins un caroténoïde et de vitamine C.The present invention further relates to a method of cosmetic treatment of the skin intended to stimulate the synthesis of collagen and / or fight against skin disorders linked to age and / or menopause and / or fight against thinning. of the dermis and / or combat the appearance of soft and / or wrinkled skin, characterized in that ('it is applied to the skin, on the hair, on the hair and / or on the mucous membranes or which is ingested a cosmetic composition comprising at least the combination of at least one carotenoid and vitamin C.
Le procédé de traitement cosmétique de l'invention peut être mis en œuvre notamment en appliquant les compositions cosmétiques telles que définies ci-dessus, selon la technique d'utilisation habituelle de ces compositions. Par exemple : application de crèmes, de gels, de sérums, de lotions, de laits, de shampooings ou de compositions anti-solaires, sur la peau ou sur les cheveux ou sur les poils ou encore application de dentifrice sur les gencives et de manière préférentielle par administration par voie orale d'une solution buvable, d'un sirop, d'un comprimé, d'une gélule, d'une capsule ou encore un aliment nutrîtîonnel ou d'un complément nutrîtîonnel.The cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique for using these compositions. For example: application of creams, gels, serums, lotions, milks, shampoos or sunscreen compositions, on the skin or on the hair or on the hairs or also application of toothpaste on the gums and so preferable by oral administration of an oral solution, a syrup, a tablet, a capsule, a capsule or a nutrient food or a nutrient supplement.
Les exemples et compositions suivants illustrent l'invention sans la limiter aucunement. Dans les compositions les proportions indiquées sont des pourcentages en poids.The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight.
Composition 1 - Capsules molles : Excipients : Huile de Soja 40 mgComposition 1 - Soft capsules: Excipients: Soybean Oil 40 mg
Huile de Germe de Blé 85 mgWheat Germ Oil 85 mg
Lécîthines de Soja 25 mgSoy Lecithins 25 mg
Vitamines ; Tocophérols naturels 3 mgVitamins; Natural Tocopherols 3 mg
Vitamine C 60 mgVitamin C 60 mg
Composants :Components:
Lycopène 6 mg Isoflavones de soja 50 mgLycopene 6 mg Soy isoflavones 50 mg
Composition 2 : Crème de soin (émulsion huile dans eau,'Composition 2: Care cream (oil in water emulsion, '
Lycopène à 6% (LycomatoΘ) 0,001 %Lycopene 6% (LycomatoΘ) 0.001%
Vitamine C 5.00% Stéarate de glycέrol 2.00'%Vitamin C 5.00% Glycrol stearate 2.00 '%
Polysorbate 60 (Tween 60' vendu par la société ICI) 1.00%Polysorbate 60 (Tween 60 'sold by ICI) 1.00%
Acide stéarique 1 ,40%Stearic acid 1.40%
Trièthanolarnine 0,70%Triethanolamine 0.70%
Carbomer 0.40% Fraction, liquide du beurre de karîté 12 ,00%Carbomer 0.40% Fraction, shea butter liquid 12.00%
Perhydrosqualène 12,00%Perhydrosqualene 12.00%
Antioxydant 0,05%Antioxidant 0.05%
Parfum 0,50% Conservateur 0,30% Eau qsp 100,00%Perfume 0.50% Preservative 0.30% Water qs 100.00%
Composition 3 : Gel pour la peau Lycopène à 6% (Lycomato®) 0,0001 %Composition 3: Lycopene 6% skin gel (Lycomato®) 0.0001%
Vitamine C 5,00%Vitamin C 5.00%
Isoflavones de soja 0,001 %Soy isoflavones 0.001%
Acide tout trans rétînoïque ,0,05%All trans retinoic acid, 0.05%
Hydroxypropylcellulose (Klucel H® vendu par la société Hercules) 1 ,00% Antioxydant 0,05%Hydroxypropylcellulose (Klucel H ® sold by the company Hercules) 1.00% Antioxidant 0.05%
Isopropanol 40,00%Isopropanol 40.00%
Conservateur 0,30% Eau qsp 100,00%Preservative 0.30% Water qs 100.00%
Composition 4 : Crème de soin (émulsion huile-dans-eau)Composition 4: Care cream (oil-in-water emulsion)
Lycopène à 6% (Lycomato®) 0,01 %Lycopene 6% (Lycomato®) 0.01%
Vitamine C 2,00%Vitamin C 2.00%
Stéarate de glycérol 2,00% Polysorbate 60 (Tween 60® vendu par la société ICI) 1 ,00%Glycerol stearate 2.00% Polysorbate 60 (Tween 60 ® sold by the company ICI) 1.00%
Acide stéarique 1 ,40%Stearic acid 1.40%
Acide glycyrrhétînique 2,00%Glycyrrhetinic acid 2.00%
Triéthanolamine 0.70%Triethanolamine 0.70%
Carbomer 0.40% Fraction liquide du beurre de karité 12.00%Carbomer 0.40% Liquid fraction of shea butter 12.00%
Huile de tournesol 1 0.00%Sunflower oil 1 0.00%
Antioxydant 0,05%Antioxidant 0.05%
Parfum 0,50%Perfume 0.50%
Conservateur 0.30% Eau qsp 100,00% Preservative 0.30% Water qs 100.00%
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002214105A AU2002214105A1 (en) | 2000-10-26 | 2001-10-25 | Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/13758 | 2000-10-26 | ||
FR0013758A FR2815864B1 (en) | 2000-10-26 | 2000-10-26 | USE OF A COMBINATION OF AT LEAST ONE CAROTENOID AND VITAMIN C TO TREAT SKIN SIGNS OF AGING |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002034210A2 true WO2002034210A2 (en) | 2002-05-02 |
WO2002034210A3 WO2002034210A3 (en) | 2002-06-27 |
Family
ID=8855774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003318 WO2002034210A2 (en) | 2000-10-26 | 2001-10-25 | Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002214105A1 (en) |
FR (1) | FR2815864B1 (en) |
WO (1) | WO2002034210A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009534317A (en) * | 2006-04-12 | 2009-09-24 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Oral composition having anti-aging effect on skin |
WO2010064210A1 (en) | 2008-12-03 | 2010-06-10 | Laboratoires Inneov Snc | Combination of lycopene, polyphenol, and vitamins for the care of keratin material |
WO2014049561A2 (en) | 2012-09-28 | 2014-04-03 | Laboratoires Inneov | Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound |
US8987329B2 (en) | 2006-04-12 | 2015-03-24 | Conopco, Inc. | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10301631A1 (en) * | 2003-01-17 | 2004-07-29 | Beiersdorf Ag | Cosmetic and dermatological composition, useful e.g. for restructuring and rejuvenating skin, contains soya bean germ extract, vitamins C and E and alpha-glycosylrutin |
FR2895255B1 (en) * | 2005-12-22 | 2008-11-07 | Oreal | COMPOSITION COMPRISING AN EXTRACT OF NONSURFUCTIVE NON PHOTOSYNTHETIC FILAMENTARY BACTERIUM AND VITAMIN C OR ONE OF ITS DERIVATIVES STABILIZED BY A COPOLYMER. |
FR2895254B1 (en) * | 2005-12-22 | 2008-02-15 | Oreal | TREATMENT CARE KIT COMPRISING EXTRACT OF NON-PHOTOSYNTHETIC NON-FRUCTIFIANT FILAMENTARY BACTERIUM AND COSMETIC ACTIVE. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY102648A (en) * | 1986-12-03 | 1992-08-17 | Rudov David | Pharmacological / cosmetic preparation |
US5290605A (en) * | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
JP2879959B2 (en) * | 1990-09-05 | 1999-04-05 | 鐘紡株式会社 | Lip composition |
JPH05320036A (en) * | 1992-05-19 | 1993-12-03 | Shiseido Co Ltd | Composition for eliminating singlet oxygen |
FR2698268B1 (en) * | 1992-11-24 | 1995-01-20 | Oreal | Photoprotective composition administered orally. |
FR2727018B1 (en) * | 1994-11-17 | 1997-01-31 | Jcb Cosmetiques | ORAL COMPOSITION FOR THE PREVENTION OF SOLAR ALLERGIES BASED ON A CAROTENOID, A TOCOPHEROL, ASCORBIC ACID AND SELENIUM |
FR2749758B1 (en) * | 1996-06-12 | 1998-08-07 | Oenobiol Sa Lab | COMPOSITION WITH TANNING AND PHOTOPROCTOR ACTIVITY AND ITS AESTHETIC APPLICATIONS |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
US5804386A (en) * | 1997-01-15 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Sets of labeled energy transfer fluorescent primers and their use in multi component analysis |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
AT407821B (en) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | MEDIUM BASED ON NATURAL SUBSTANCES |
DE19838636A1 (en) * | 1998-08-26 | 2000-03-02 | Basf Ag | Carotenoid formulations containing a mixture of beta-carotene, lycopene and lutein |
-
2000
- 2000-10-26 FR FR0013758A patent/FR2815864B1/en not_active Expired - Lifetime
-
2001
- 2001-10-25 AU AU2002214105A patent/AU2002214105A1/en not_active Abandoned
- 2001-10-25 WO PCT/FR2001/003318 patent/WO2002034210A2/en active Application Filing
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009534317A (en) * | 2006-04-12 | 2009-09-24 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Oral composition having anti-aging effect on skin |
US8987329B2 (en) | 2006-04-12 | 2015-03-24 | Conopco, Inc. | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
WO2010064210A1 (en) | 2008-12-03 | 2010-06-10 | Laboratoires Inneov Snc | Combination of lycopene, polyphenol, and vitamins for the care of keratin material |
US9000049B2 (en) | 2008-12-03 | 2015-04-07 | Laboratories Inneov SNC | Combination of lycopene, polyphenol, and vitamins for the care of keratin materials |
WO2014049561A2 (en) | 2012-09-28 | 2014-04-03 | Laboratoires Inneov | Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound |
FR2996135A1 (en) * | 2012-09-28 | 2014-04-04 | Inneov Lab | ORAL COMPOSITION FOR ENHANCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF RETINOID COMPOUND |
WO2014049561A3 (en) * | 2012-09-28 | 2014-11-06 | Laboratoires Inneov | Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound |
US10022315B2 (en) | 2012-09-28 | 2018-07-17 | Laboratoires Inneov | Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound |
Also Published As
Publication number | Publication date |
---|---|
FR2815864A1 (en) | 2002-05-03 |
WO2002034210A3 (en) | 2002-06-27 |
FR2815864B1 (en) | 2003-02-28 |
AU2002214105A1 (en) | 2002-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064931B1 (en) | Cosmetic composition containing at least one hydroxystilbene and ascorbic acid | |
EP1090628B1 (en) | Use of lycopene in compositions for treating ageing skin symptoms | |
EP0953346B1 (en) | Use of at least a hydroxystilbene in a skin fortifying composition | |
EP1195156A1 (en) | Use of an ericaceae extract in skin-ageing treatment | |
CA2255229C (en) | Use of cinnamic acid, or of its derivatives, as a firming agent in a cosmetic composition | |
US20090227688A1 (en) | Admixture of carotenoids having provitamin a activity and carotenoids devoid of provitamin a activity for treating aging symptoms | |
FR2759292A1 (en) | USE OF RETINOIDS AS PIGMENTATION INDUCING AGENTS | |
EP1331925A2 (en) | Use of an association of at least a carotenoid and of at least an isoflavonoid for treating cutaneous symptoms of ageing | |
FR2812544A1 (en) | Treatment of cutaneous aging symptoms, such as wrinkles, comprises topical or oral administration of Salvia genus plant extracts with collagenase expression inhibiting activity | |
CA2407294A1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
WO2002034210A2 (en) | Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing | |
US20090123573A1 (en) | Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging | |
FR2821549A1 (en) | Use of a carotenoid to increase dermal collagen and lessen or prevent signs of cutaneous aging | |
WO2002034276A2 (en) | Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid | |
FR2829388A1 (en) | Use of carotenoids in cosmetic compositions e.g. for stimulating keratinocyte proliferation, inhibiting keratinocyte differentiation, promoting epidermal renewal or regeneration or promoting wound healing | |
EP1401390A1 (en) | Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cutaneous signs of ageing | |
FR2772611A1 (en) | Cosmetic compositions containing auxin, preferably beta-naphthoxyacetic acid, to stimulate collagen synthesis, useful e.g. for combating cutaneous aging | |
FR2799368A1 (en) | Use of lycopene for the preparation of a composition for preventing or treating signs of aging in skin, particularly used to prevent wrinkles or dermis thinning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |